

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 80205

Title: Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06196079

Position: Peer Reviewer

Academic degree: MD

Professional title: Attending Doctor, Lecturer

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2022-09-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-08 03:57

Reviewer performed review: 2022-10-17 12:56

Review time: 9 Days and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors wrote a review article about the nanomedicine-based multimodal therapies in colon cancer. As colon cancer is an important GI diseases and also an important malignant diseases. The development of new treatment is promising and beneficial for the patients. The article is well written and educational. There are several points that may need further clarification. 1. There's a generalized question, how could these nano-medicine been distributed into specific colon cancer cell, by IV, PO or colonoscopy topical treatment? Nanoparticles may also elicit toxicity by disrupting membranes within the cell, how about the safety profile and potential adverse events of Nano-medicine in colon cancer treatment 1. The authors talked about anti-inflammatory drugs, natural product's role in colon cancer, however, are they nano-medicine? Please describe more specifically and may delete them if they're not nanomedicine. Similar question also exist in the role of metronidazole in chemotherapy. 2. In phototherapy part, H₂S was also frequently noted in patients with irritable bowel syndrome and inflammatory bowel syndrome, is this treatment toward H₂S focus only on colon cancer treatment or also other GI disease. 3. The authors mentioned many nanomedicine, is



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

there any therapy which had been available in clinical practice or completed phase III clinical trial, the authors may can make a summary table of the treatments currently on phase I to phase III clinical trial, especially those on phase III clinical trial whichc is predicted to be on market soon. 5. Metastatic colon cancer is the main cause of colon cancer related mortality, the authors mentinoned about PDL-L1 blocking ability nanoparticles, what is its diffrence comparing with current anti-PD1 treatment? Is there any OTHER nanomedicne focusing on cancer cells which easily metastate or metastatic cancer? Will the metastatic site influence the application of nonomedicine? 6. The authors stated that "Nanomedicine-based immunotherapy has been widely used in the treatment of colon cancer." However, the reference above are most cell and animal model. Please specify it.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 80205

Title: Nanomedicine-based multimodal therapies: Recent progress and perspectives in colon cancer

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05755618

Position: Peer Reviewer

Academic degree: FACP, MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-09-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-09 05:21

Reviewer performed review: 2022-11-10 22:37

Review time: 1 Day and 17 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The article reviewed narratively about applying nano-medicine to colonic cancer. It is an exciting report. Although several other nano-medicines for cancers have been reported, there have been no reports focusing on colonic cancer previously. Therefore, the contents of the article are fit for the journal. However, there are some concerns about this article. 1. Please describe the literature search methods. The authors could make the flowchart as a figure. 2. The number of references is small for a full review article. 3. Is there applying artificial intelligence for nano-medicine for colonic cancer? 4. Please state the primary and secondary outcomes at the end of the introduction.